42Stockpicking

DYN

Dyne Therapeutics IncKøb· 86.2%· 9. jun. 2026
NASDAQ·Healthcare·USD

Henter pris…

Værdiansættelse (TTM)

P/Ei
EV/EBITDAi
P/Bi
3,3
50th %ile · 404p
P/Si
EV/Salesi
Div yieldi

Kursudvikling

Kun 77 handelsdage i databasen. Viser al tilgængelig historik.

Pris

Data-readiness

10 års prishistorik er idealet for høj confidence.

Beregnet 10.6.2026none
Prishistorik
0,3 år
Pris-dage
77
Årsregnskaber
8
Peers
0/0
Valuation
1/6
Fundamentals
6/8
Datovindue
2026-02-09 til 2026-05-29

Blokkere

  • Raw confidence is below the 0.95 high-confidence guardrail.

Mangler før højere confidence

  • Mangler ca. 9,7 års prishistorik før ideal/full.
  • Backfill mindst 1 års daglige priser før seriøs teknisk vurdering.
  • Kør compute-multiples for manglende valuation metrics.
  • Kør fetch-fundamentals-bulk/API fallback for manglende regnskabsmetrics.

Seneste assessment

DYN vurderet 2026-06-10

Score
30.9%
Ikke high-confidence

Raw confidence is below the 0.95 high-confidence guardrail.

Sell watch placeholder

Stores exit-aware fields without issuing sell scores yet.

63%

Current drawdown: Future exit logic can use drawdown from recent high.

Trend break: Future exit logic can use moving-average trend breaks.

Valuation

Compares price paid with earnings, cash-generation proxies and sales.

45%

P/E: Reasonable P/E gets rewarded; very expensive or distressed multiples do not.

Earnings yield: Earnings yield is the inverse P/E lens.

Technicals

Checks trend, momentum and current damage from recent highs.

63%

6M momentum: Positive medium-term momentum confirms sponsorship.

Trend stack: Strong setup keeps price above MA50 and MA200 with MA50 above MA200.

Data quality

Checks whether the assessment has enough recent price, fundamental and valuation data.

42%

Price history depth: More than one trading year gives the technical pillar enough context.

Latest price freshness: Latest live or EOD price should be recent.

Macro/regime

Treats macro as context, not a standalone trading instruction.

46%

VIX: Normal volatility is supportive; panic or complacency is less clean.

10Y-2Y curve: Positive yield curve lowers recession stress.

Fundamentals

Scores growth, margins, capital efficiency, balance-sheet resilience and composite financial-health KPIs.

40%

Revenue growth 3Y: Sustained top-line growth supports durable compounding.

Gross margin: High gross margin gives room for reinvestment and downturns.

Peer/relative context

Adds relative context when sector peers have comparable data.

42%

Peer count: Peer context is only scored when comparable data exists.

P/E vs peers: P/E relative valuation needs both own multiple and peer median.

Insider activity

Net 90d (aktier)
-85.621
Net 90d (værdi)
-1.727.262 USD
Købere 90d
1
Cluster
DatoPersonRolleTypeAntalVærdiKilde
18.6.2026Kersten Dirk▼ SALG-46.901-941.373 USDsec
17.6.2026Kersten Dirk▼ SALG-37.454-754.316 USDsec
16.6.2026Friedl-Naderer JohannaChief Commercial Officer▼ SALG-145-2.658 USDsec
16.6.2026Kerr DouglasChief Medical Officer▼ SALG-887-16.259 USDsec
16.6.2026Cox JohnCEO & President▼ SALG-2.683-49.179 USDsec
8.6.2026Posner Brian S▲ KØB2.00033.880 USDsec
3.6.2026Posner Brian S▲ KØB2.50043.700 USDsec
26.5.2026Posner Brian S▲ KØB2.00036.420 USDsec
20.5.2026Posner Brian S▲ KØB2.50042.800 USDsec
13.5.2026Cox JohnCEO & President▼ SALG-3.311-60.790 USDsec
13.5.2026Friedl-Naderer JohannaChief Commercial Officer▼ SALG-228-4.186 USDsec
13.5.2026Kerr DouglasChief Medical Officer▼ SALG-1.564-28.715 USDsec
13.5.2026Lucera ErickChief Financial Officer▼ SALG-1.448-26.585 USDsec

Earnings

QuarterDateEPS actualEPS estEPS surpriseRevenue surprise
2026Q130.4.2026-0,73-0,78+6.7%+6.7%Beat
2025Q430.1.2026-0,73-0,76+4.4%+4.4%Inline
2025Q330.10.2025-0,76-0,85+10.1%+10.1%Beat
2025Q230.7.2025-0,97-0,93-3.9%-3.9%Inline